When Reeda Aafreen Sayed enrolled in the Master of Science in Pharmacology at the University of Vermont (UVM) in 2025, she was drawn by the program’s reputation for crossing traditional departmental lines. Rather than being confined to a single laboratory, the curriculum encouraged collaboration across multiple research hubs, giving her the freedom to pursue questions that sit at the intersection of chemistry, genetics, and cell biology.
Why an interdisciplinary environment mattered
In interviews, Reeda emphasized that the ability to engage with scholars outside the strict confines of the Pharmacology Department was a decisive factor. Interdisciplinary research is increasingly recognized as a catalyst for breakthroughs, especially in fields where molecular mechanisms interact with therapeutic outcomes. At UVM, she could tap into resources from the Genetics Institute, the Biochemistry Core, and even the Department of Molecular Biology, allowing her to construct a more holistic view of drug action.
Delving into histone acetylation and epigenetic control
Reeda’s project centers on histone acetylation, a type of epigenetic modification that influences how tightly DNA winds around histone proteins. By adding acetyl groups, cells can loosen the chromatin structure, making specific genes more accessible for transcription. In her own words, she is fascinated by how these chemical tags act like switches, turning genes on or off in response to environmental cues. Her experiments employ chromatin immunoprecipitation coupled with next-generation sequencing to map acetylation patterns across the genome, seeking to link these patterns with changes in cellular behavior.
Connecting chromatin architecture to disease pathways
The ultimate goal of Reeda’s work is to translate basic epigenetic insights into therapeutic strategies. Aberrant histone acetylation has been implicated in cancer, neurodegeneration, and metabolic disorders. By characterizing the precise modifications that govern gene expression in model systems, she hopes to identify potential drug targets that could correct faulty epigenetic signaling. This line of inquiry aligns with the broader mission of UVM’s pharmacology program to train scientists who can bridge bench-side discoveries with bedside applications.
Mentorship that shapes a research identity
Since her first semester, Reeda has cultivated one-on-one mentorship relationships with faculty members from several departments. She describes the professors as “approachable and deeply invested in student growth,” qualities that have turned routine lab meetings into dynamic learning experiences. The personalized feedback loops have sharpened her experimental design skills, taught her how to critique data rigorously, and provided career-building advice ranging from grant writing to conference networking.
Looking ahead: From graduate study to scientific contribution
While Reeda’s master’s journey is still unfolding, the foundation she is building at UVM positions her for future endeavors in academia or industry. The blend of interdisciplinary exposure, cutting-edge epigenetic research, and strong mentorship equips her to tackle complex drug-development challenges. As she prepares to publish her first manuscript, she remains focused on expanding the knowledge base around histone acetylation, hoping that her findings will one day inform novel pharmacological interventions.
